Ovarian cancer proteomics: Many technologies one goal

Proteomics - Clinical Applications

Volumn 2, Issue 2, 2008, Pages 195-218

  Narasimhan, Kothandaraman ^a   Changqing, Zhao ^a   Choolani, Mahesh ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Biomarkers; Ovarian cancer; Protein array; Protein profiling

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CANCER ANTIBODY; COMPLEMENTARY DNA; CYTOKINE; GLYCOPROTEIN; KALLIKREIN; MESSENGER RNA; OSTEOPONTIN; QUANTUM DOT; TUMOR ANTIGEN; TUMOR MARKER;

BIOINFORMATICS; BIOTECHNOLOGY; BODY FLUID; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER STAGING; DIAGNOSTIC VALUE; DNA MICROARRAY; EARLY DIAGNOSIS; ECHOGRAPHY; ELECTROSPRAY MASS SPECTROMETRY; GENE EXPRESSION PROFILING; HIGH THROUGHPUT SCREENING; HUMAN; LAB ON A CHIP; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLITE; METABOLOMICS; MOLECULAR BIOLOGY; NANOTECHNOLOGY; NONHUMAN; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN GLYCOSYLATION; PROTEIN MICROARRAY; PROTEIN TARGETING; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TISSUE MICROARRAY; VALIDATION PROCESS;

EID: 39649086914     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780003     Document Type: Review

References (174)

1. Bast, R. C., Jr., Xu, F. J., Yu, Y. H., Barnhill, S. et al., CA-125: The past and the future. Int. J. Biol. Markers 1998, 13, 179-187.
2. Holschneider, C. H., Berek, J. S., Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin. Surg. Oncol. 2000, 19, 3-10.
3. Bristow, R. E., Berek, J. S., Surgery for ovarian cancer: How to improve survival. Lancet 2006, 367, 1558-1560.
4. Jemal, A., Siegel, R., Ward, E., Murray, T. et al., Cancer statistics. CA Cancer J Clin. 2007, 57, 43-66.
5. Kristensen, G. B., Trope, C., Epithelial ovarian carcinoma. Lancet 1997, 349, 113-117.
6. van Nagell, J. R., Jr., DePriest, P. D., Reedy, M. B., Gallion, H. H. et al., The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol. Oncol. 2000, 77, 350-356.
7. Rosenthal, A. N., Jacobs, I. J., The role of CA 125 in screening for ovarian cancer. Int. J. Biol. Markers 1998, 13, 216-220.
8. Nguyen, H. N., Averette, H. E., Hoskins, W., Sevin, B. U. et al., Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer 1993, 72, 3007-3011.
9. Kurjak, A., Shalan, H., Matijevic, R., Predanic, M., Kupesic-Urek, S., Stage I ovarian cancer by transvaginal color Doppler sonography: A report of 18 cases. Ultrasound Obstet. Gynecol. 1993, 3, 195-198.
10. Fleischer, A. C., Cullinan, J. A., Peery, C. V., Jones, H. W., III, Early detection of ovarian carcinoma with transvaginal color Doppler ultrasonography. Am. J. Obstet. Gynecol. 1996, 174, 101-106.
11. Jacobs, I., Oram, D., Fairbanks, J., Turner, J., A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br. J. Obstet. Gynaecol. 1990, 97, 922-929.
12. Tingulstad, S., Hagen, B., Skjeldestad, F. E., Onsrud, M. et al., Evaluation of a risk of malignancy index based on serum CA-125, ultrasound findings and menopausal status in the preoperative diagnosis of pelvic masses. Br. J. Obstet. Gynaecol. 1996, 103, 826-831.
13. Tingulstad, S., Hagen, B., Skjeldestad, F. E., Halvorsen, T. et al., The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet. Gynecol. 1999, 93, 448-452.
14. Aslam, N., Tailor, A., Lawton, F., Carr, J. et al., Prospective evaluation of three different models for the pre-operative diagnosis of ovarian cancer. BJOG 2000, 107, 1347-1353.
15. Bast, R. C., Jr., Knapp, R. C., Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol. 1985, 19, 354-356.
16. Bast, R. C., Jr., Klug, T. L., St John, E., Jenison, E. et al., A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J, Med. 1983, 309, 883-887.
17. Daoud, E., Bodor, G., CA-125 concentrations in malignant and nonmalignant disease. Clin. Chem. 1991, 37, 1966-1974,
18. Jacobs, I., Bast, R. C., Jr., The CA 125 tumour-associated antigen: A review of the literature. Hum. Reprod, 1989, 4, 1-12.
19. Miles, A. K., Matharoo-Ball, B., Li, G., Ahmad, M., Rees, R. C., The identification of human tumour antigens: Current status and future developments. Cancer Immunol. Immunother. 2006, 55, 996-1003.
20. Yousef, G. M., Diamandis, E. P. Tissue kallikreins: New players in normal and abnormal cell growth? Thromb. Haemost. 2003, 90, 7-16.
21. Bast, R. C., Jr., Badgwell, D., Lu, Z. et al., CA-125 and beyond. Int. J. Gynecol. Cancer 2005, 15, 3, 274-281.
22. Oikonomopoulou, K., Scorilas, A., Michael, I. P, Grass, L. et al., Kallikreins as markers of disseminated tumour cells in ovarian cancer-a pilot study. Tumour Biol. 2006, 27, 104-114.
23. Borgono, C. A., Kishi, T., Scorilas, A., Harbeck, N. et al., Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Clin. Cancer Res. 2006, 12, 1487-1493.
24. Shaw, J. L., Diamandis, E. P., Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007, 53, 1423-1432.
25. Paliouras, M., Borgono, C., Diamandis, E. P., Human tissue kallikreins: The cancer biomarker family. Cancer Lett. 2007; 249, 61-79.
26. Olsson, A. Y., Bjartell, A., Lilja, H., Lundwall, A., Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. Int. J. Cancer 2005, 113, 290-297.
27. Luo, L. Y., Shan, S. J., Elliott, M. B., Soosaipillai, A. et al., Purification and characterization of human kallikrein 11, a candidate prostate and ovarian cancer biomarker, from seminal plasma. Clin. Cancer Res. 2006, 12, 742-750.
28. Gorelik, E., Landsittel, D. P., Marrangoni, A. M., Modugno, F. et al., Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 981-987.
29. Le Page, C., Ouellet, V., Madore, J., Hudson, T. J. et al., From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA-125 as serum-based markers in epithelial ovarian cancer. Int. J. Cancer 2006, 118, 1750-1758.
30. Brakora, K. A., Lee, H., Yusuf, R., Sullivan, L. et al., Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol. Oncol. 2004, 93, 361-365.
31. Schorge, J. O., Drake, R. D., Lee, H., Skates, S. J. et al., Osteopontin as an adjunct to CA-125 in detecting recurrent ovarian cancer. Clin. Cancer Res. 2004, 10, 3474-3478.
32. Draghici, S., Chatterjee, M., Tainsky, M. A., Epitomics: Serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens. Expert Rev. Mol. Diagn. 2005, 5, 735-743.
33. Carr, T. M., Adair, S. J., Fink, M. J., Hogan, K. T., Immunological profiling of a panel of human ovarian cancer cell lines. Cancer Immunol. Immunother. 2007, 57, 31-42.
34. Malyankar, U. M., Tumor-associated antigens and biomarkers in cancer and immune therapy. Int. Rev. Immunol. 2007, 26, 223-247.
35. Chatterjee, M., Mohapatra, S., Ionan, A., Bawa, G. et al., Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. 2006, 66, 1181-1190.
36. Luborsky, J. L., Barua, A., Shatavi, S. V., Kebede, T. et al., Anti-tumor antibodies in ovarian cancer. Am. J. Reprod. Immunol. 2005, 54, 55-62.
37. Friedenson, B., BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. Med. Gen. Med. 2005, 7, 60.
38. Godwin, A. K., Testa, J. R., Hamilton, T. C., The biology of ovarian cancer development. Cancer 1993, 71, 530-536.
39. Katabuchi, H., Okamura, H., Cell biology of human ovarian surface epithelial cells and ovarian carcinogenesis. Med. Electron Microsc. 2003, 36, 74-86.
40. Wong, A. S., Auersperg, N., Ovarian surface epithelium: Family history and early events in ovarian cancer. Reprod. Biol. Endocrinol. 2003, 1, 70.
41. Adib, T. R, Henderson, S., Perrett, C., Hewitt, D. et al., Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br. J. Cancer 2004, 90, 686-692.
42. Heinzelmann-Schwarz, V. A., Gardiner-Garden, M., Henshall, S. M., Scurry, J. et al., Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin. Cancer Res. 2004, 10, 4427-4436.
43. Suzuki, M., Kobayashi, H., Tanaka, Y., Hirashima, Y. et al., Bikunin target genes in ovarian cancer cells identified by microarray analysis. J. Biol. Chem. 2003, 278, 14640-14646.
44. Mok, S. C., Chao, J., Skates, S., Wong, K. et al., Prostasin, a potential serum marker for ovarian cancer: Identification through microarray technology. J. Natl. Cancer Inst. 2001, 93, 1458-1464.
45. Kim, J. H., Skates, S. J., Uede, T., Wong, K. K. et al., Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002, 287, 1671-1679.
46. D'Andrilli, G., Kumar, C., Scambia, G., Giordano, A., Cell cycle genes in ovarian cancer: Steps toward earlier diagnosis and novel therapies. Clin. Cancer Res. 2004, 10, 8132-8141,
47. Davidson, B., Espina, V., Steinberg, S. M., Florenes, V. A. et al., Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin. Cancer Res. 2006, 12, 791-799.
48. Reimer, D., Sadr, S., Wiedemair, A., Stadlmann, S. et al., Clinical relevance of E2F family members in ovarian cancer - an evaluation in a training set of 77 patients. Clin. Cancer Res. 2007, 13, 144-151.
49. Libermann, T. A., Zerbini, L. F., Targeting transcription factors for cancer gene therapy. Curr. Gene Ther. 2006, 6, 17-33.
50. Zhang, Z., Bast, R. C., Jr., Yu, Y., Li, J. et al., Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64, 5882-5890.
51. Mor, G., Visintin, I., Lai, Y., Zhao, H. et al., Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 7677-7682.
52. Kopreski, M. S., Benko, F. A., Gocke, C. D., Circulating RNA as a tumor marker: Detection of 5T4 mRNA in breast and lung cancer patient serum. Ann. N. Y. Acad. Sci. 2001, 945, 172-178.
53. Bast, R. C., Jr., Brewer, M., Zou, C., Hernandez, M. A. et al., Prevention end early detection of ovarian cancer: Mission impossible? Cancer Res. 2007, 174, 91-100.
54. Huddleston, H. G., Wong, K. K., Welch, W. R, Berkowitz, R. S., Mok, S. C. Clinical applications of microarray technology: Creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol. Oncol. 2005, 96, 77-83.
55. Simon, I., Zhuo, S., Corral, L., Diamandis, E. P. et al., B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 2006, 66, 1570-1575.
56. Rai, A. J., Chan, D. W., Cancer proteomics: Serum diagnostics for tumor marker discovery. Ann. N. Y. Acad. Sci. 2004, 1022, 286-294.
57. Van den Bergh, G., Arckens, L., Recent advances in 2D electrophoresis: An array of possibilities. Expert Rev. Proteomics 2005, 2, 243-252.
58. Wall, D. B., Kachman, M. T., Gong, S. S., Parus, S. J. et al., Isoelectric focusing nonporous silica reversed-phase high-performance liquid chromatography/electrospray ionization time-of-flight mass spectrometry: A three-dimensional liquid-phase protein separation method as applied to the human erythroleukemia cell-line. Rapid Commun. Mass Spectrom. 2001, 15, 1649-1661.
59. Conrads, T. P., Anderson, G. A., Veenstra, T. D., Pasa-Tolic, L., Smith, R. D., Utility of accurate mass tags for proteome-wide protein identification. Anal. Chem. 2000, 72, 3349-3354.
60. Umar, A., Luider, T. M., Foekens, J. A., Pasa-Tolić, L., NanoLC-FT-ICR MS improves proteome coverage attainable for approximately 3000 laser-microdissected breast carcinoma cells. Proteomics 2007, 7, 323-329.
61. Tang, N., Tornatore, P., Weinberger, S. R., Current developments in SELDI affinity technology. Mass Spectrom. Rev. 2004, 23, 34-44.
62. Reyzer, M. L., Caprioli, R. M., MALDI mass spectrometry for direct tissue analysis: A new tool for biomarker discovery. J. Proteome Res. 2005, 4, 1138-1142.
63. Bons, J. A., Wodzig, W. K., van Dieijen-Visser, M. P., Protein profiling as a diagnostic tool in clinical chemistry: A review. Clin. Chem. Lab. Med. 2005, 43, 1281-1290.
64. Radulovic, D., Jelveh, S., Ryu, S., Hamilton, T. G. et al., Informatics platform for global proteomic profiling and biomarker discovery using liquid chromatography-tandem mass spectrometry. Mol. Cell. Proteomics 2004, 3, 984-997.
65. Nelson, R. W., Krone, J. R., Bieber, A. L., Williams, P., Mass spectrometric immunoassay. Anal. Chem. 1995, 67, 1153-1168.
66. Denkert, C., Budczies, J., Kind, T., Weichert, W. et al., Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 2006, 66, 10795-10804.
67. Song, J., Patel, M., Rosenzweig, C. N., Chan-Li, Y. et al. Quantification of fragments of human serum inter-alphatrypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin. Chem. 2006, 52, 1045-1053.
68. Dekker, L. J., Boogerd, W., Stockhammer, G., Dalebout, J. C. et al. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol. Cell. Proteomics 2005, 4, 1341-1349.
69. Conrads, T. P., Fusaro, V. A., Ross, S., Johann, D. et al., High-resolution serum proteomic features for ovarian cancer detection. Endocr. Relat. Cancer 2004, 11, 163-178.
70. An, H. J., Miyamoto, S., Lancaster, K. S., Kirmiz, C. et al., Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J. Proteome Res. 2006, 5, 1626-1635.
71. Garvin, A. M. G., Parker, K. C., Haff, L., MALDI-TOF based mutation detection using tagged in vitro synthesized peptides. Nat. Biotechnol. 2000, 18, 95-97.
72. Yu, W., Wu, B., Lin, N., Stone, K. et al., Detecting and aligning peaks in mass spectrometry data with applications to MALDI. Comput. Biol. Chem. 2006, 30, 27-38.
73. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J. et al., Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359, 572-577.
74. Wang, H., Kachman, M. T., Schwartz, D. R., Cho, K. R. et al. Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: A strategy for identification of candidate cancer biomarkers. Proteomics 2004, 4, 2476-2495.
75. Kachman, M. T., Wang, H., Schwartz, D. R., Cho, K. R. et al. A 2-D liquid separations/mass mapping method for interlysate comparison of ovarian cancers. Anal. Chem. 2002, 74, 1779-1791.
76. Zhu, Y., Wu, R., Sangha, N., Yoo, C. et al., Classifications of ovarian cancer tissues by proteomic patterns. Proteomics 2006, 6, 5846-5856.
77. Poon, T. C., Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev. Proteomics 2007, 4, 51-65.
78. Gericke, B., Raila, J., Sehouli, J., Haebel, S. et al. Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer 2005, 5, 133.
79. Wright, G. L., Jr., Cazares, L. H., Leung, S. M., Nasim, S. et al., Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: A novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis. 1999, 2, 264-276.
80. Xiao, Z., Adam, B. L., Cazares, L. H., Clements, M. A. et al., Quantitation of serum prostatespecific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 2001, 61, 6029-6033.
81. Fung, E. T., Yip, T. T., Lomas, L., Wang, Z. et al., Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int. J. Cancer 2005, 115, 783-789.
82. Geho, D. H., Lahar, N., Ferrari, M., Petricoin, E. F., Liotta, L. A., Opportunities for nanotechnology-based innovation in tissue proteomics. Biomed. Microdevices 2004, 6, 231-239.
83. Chaurand, P., Schwartz, S. A., Caprioli, R. M., Assessing protein patterns in disease using imaging mass spectrometry. J. Proteome Res. 2004, 3, 245-252.
84. Schwartz, S. A., Weil, R. J., Johnson, M. D., Toms, S. A., Caprioli, R. M., Protein profiling in brain tumors using mass spectrometry: Feasibility of a new technique for the analysis of protein expression. Clin. Cancer Res. 2004, 10, 981-987.
85. Schwartz, S. A., Weil, R. J., Thompson, R. C., Shyr, Y. et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res. 2005, 65, 7674-7681.
86. Bouamrani, A., Ternier, J., Ratel, D., Benabid, A. L. et al. Direct-tissue SELDI-TOF mass spectrometry analysis: A new application for clinical proteomics. Clin. Chem. 2006, 52, 2103-2106.
87. Lopez, M. F., Mikulskis, A., Kuzdzal, S., Golenko, E. et al. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin. Chem. 2007, 53, 1067-1074.
88. Mehta, A. I., Ross, S., Lowenthal, M. S., Fusaro, V. et al. Biomarker amplification by serum carrier protein binding. Dis. Markers 2003-2004, 19, 1-10.
89. Anderson, L. V., Davison, K., Multiplex Western blotting system for the analysis of muscular dystrophy proteins. Am. J. Pathol. 1999, 154, 1017-1022.
90. Cowart, L. A., Szulc, Z., Bielawska, A., Yusuf, A., Structural determinants of sphingolipid recognition by commercially available anti-ceramide antibodies. J. Lipid Res. 2002, 43, 2042-2048.
91. Goetzl, E. J., An, S., Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine-1-phosphate. FASEB J. 1998, 12, 1589.
92. Radunz, A., On a quantitative determination of antibodies to lipids and proteins. Z. Naturforsch [C] 1983, 38, 297-301.
93. An, S., Signaling mechanisms and molecular characteristics of G-protein coupled receptors for lysophosphatidic acid and sphingosine-1-phosphate. J. Biochem. 1998, 147, 30-31.
94. Roudabeh, J., Jamasbi, R. J., Stoner, G. D., Foote, L. J. et al., A monoclonal antibody to a carbohydrate epitope expressed on glycolipid and on α3β1 integrin on human esophageal carcinoma. Hybrid. Hybridomics 2003, 22, 367-376.
95. Geisler, J. P., Hatterman-Zogg, M. A., Rathe, J. A., Lallas, T. A. et al. Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP). Hum. Mutat. 2001, 18, 337-344.
96. Kuperstein, G., Jack, E., Narod, S. A., A fluorescent multiplex-DGGE screening test for mutations in the BRCA1 gene. Genet. Test. 2006, 10, 1-7.
97. Scholler, N., Crawford, M., Sato, A., Drescher, C. W. et al., Bead-based ELISA for validation of ovarian cancer early detection markers. Clin. Cancer Res. 2006, 12, 2117-2124.
98. de Jager, W., te Velthuis, H., Prakken, B. J., Kuis, W. et al., Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood monocnuclear cells. Clin. Diagn. Lab. Immunol. 2003, 10, 133-139.
99. Oku, H., Tsuji, Y., Kashiwamura, S. I., Adachi, S. et al., Role of IL-18 in pathogenesis of endometriosis, Hum. Reprod. 2004, 19, 709-714.
100. Ellmark, P., Belov, L., Huang, P., Lee, C. S. et al. Multiplex detection of surface molecules on colorectal cancers. Proteomics 2006, 6, 1791-1802.
101. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M. et al., Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 1998, 4, 844-847.
102. Rosen, D. G., Huang, X., Deavers, M. T., Malpica, A. et al., Validation of tissue microarray technology in ovarian carcinoma. Mod. Pathol. 2004, 17, 790-797.
103. Dimova, I., Zaharieva, B., Raitcheva, S., Dimitrov, R. et al. Tissue microarray analysis of EGFR and erbB2 copy number changes in ovarian tumors. Int. J. Gynecol. Cancer 2006, 16, 145-151.
104. Wang, Y., Hewitt, S. M., Liu, S., Zhou, X. et al. Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours. Br. J. Cancer 2006, 94, 685-691.
105. Fons, G., Hasibuan, S. M., van der Velden, J., ten Kate, F. J., Validation of tissue microarray technology in endometrioid cancer of the endometrium. J. Clin. Pathol. 2007, 60, 500-503.
106. Ouellet, V., Le Page, C., Madore, J., Guyot, M. C. et al., An apoptotic molecular network identified by microarray: On the TRAIL to new insights in epithelial ovarian cancer. Cancer 2007, 110, 297-308.
107. Ouellet, V., Guyot, M. C., Le Page, C., Filali-Mouhim, A. et al., Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int. J. Cancer 2006, 119, 599-607.
108. Hoos, A., Cordon-Cardo, C., Tissue microarray profiling of cancer specimens and cell lines: Opportunities and limitations. Lab. Invest. 2001, 81, 1331-1338.
109. Aguilar-Mahecha, A., Hassan, S., Ferrario, C., Basik, M., Microarrays as validation strategies in clinical samples: Tissue end protein microarrays. OMICS 2006, 10, 311-326.
110. Janzi, M., Odling, J., Pan-Hammarström, Q., Sundberg, M. et al., Serum microarrays for large scale screening of protein levels. Mol. Cell. Proteomics 2005, 4, 1942-1947.
111. Wulfkuhle, J. D., Aquino, J. A., Calvert, V. S., Fishman, D. A. et al., Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003, 3, 2085-2090.
112. Nishizuka, S., Charboneau, L., Young, L., Major, S. et al., Proteomic profiling of the NCl-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl. Acad. Sci. USA 2003, 100, 14229-14234.
113. Abbott, R. T., Sheryl, T., Sherrie, L. P., Kojo, S. J. et al., Analysis of the PI-3-kinase-PTEN-AKT pathway in human lymphoma and leukemia using a cell line microarray. Mod. Pathol. 2003, 16, 607-612.
114. Woolas, R. P., Xu, F. J., Jacobs, I. J., Yu, Y. H. et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J. Natl. Cancer Inst. 1993, 85, 1748-1751.
115. Sheehan, K. M., Calvert, V. S., Kay, E. W., Lu, Y. et al., Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol. Cell. Proteomics 2005, 4, 346-355.
116. Templin, M. F., Stoll, D., Schrenk, M., Traub, P. C. et al., Protein microarray technology. Trends Biotechnol. 2002, 20, 160-166.
117. Immler, D., Greven. S., Reinemer, P., Targeted proteomics in biomarker validation: Detection and quantification of proteins using a multi-dimensional peptide separation strategy. Proteomics 2006, 6, 2947-2958.
118. Anderson, N. L., Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 2005, 563, 23-60.
119. Anderson, L., Hunter, C. L., Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 2006, 5, 573-588.
120. Qian, W. J., Jacobs, J. M., Liu, T., Camp, D. G., II, Smith, R. D., Advances and challenges in liquid chromatographymass spectrometry-based proteomics profiling for clinical applications. Mol. Cell. Proteomics 2006, 5, 1727-1744.
121. Denkert, C., Budczies, J., Kind, T., Weichert, W. et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 2006, 66, 10795-10804.
122. Xu, F. J., Ramakrishnan, S., Daly, L., Soper, J. T. et al., Increase serum levels of macrophage colony-stimulating factor in ovarian cancer. Am. J. Obstet. Gynecol. 1991, 165, 1356-1362.
123. Sutphen, R., Xu, Y., Wilbanks, G. D., Fiorica, J. et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2004, 13, 1185-1191.
124. Drake, R. R., Schwegler, E. E., Malik, G., Diaz, J. et al., Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol. Cell. Proteomics 2006, 5, 1957-1967.
125. Block, T. M., Comunale, M. A., Lowman, M., Steel, L. F. et al., Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc. Natl. Acad. Sci. USA 2005, 102, 779-784.
126. Comunale, M. A., Mattu, T. S., Lowman, M. A., Evans, A. A. et al., Comparative proteomic analysis of de-N-glycosylated serum from hepatitis B carriers reveals polypeptides that correlate with disease status. Proteomics 2004, 4, 826-838.
127. Sun, B., Ranish, J. A., Utleg, A. G., White, J. T. et al., Shotgun glycopeptide capture approach coupled with mass spectrometry for comprehensive glycoproteomics. Mol. Cell. Proteomics 2007, 6, 141-149.
128. Leiserowitz, G. S., Lebrilla, C., Miyamoto, S., An, H. J. et al. Glycomics analysis of serum: A potential new biomarker for ovarian cancer? Int. J. Gynecol. Cancer 2007, 26, doi: 10.1111/ j.1525-1438.2007.01028.x.
129. An, H. J., Kim, D. S., Park, Y. K., Kim, S. K. et al., Comparative proteomics of ovarian epithelial tumors. J. Proteome Res. 2006, 5, 1082-1090.
130. Nam, J. M., Thaxton, C. S., Mirkin, C. A., Nanoparticle-based bio-bar-codes for the ultrasensitive detection of proteins. Science 2003, 301, 1884-1886.
131. Christodoulides, N., Floriano, P. N., Miller, C. S., Ebersole, J. L. et al., Lab-on-a-chip methods for point-of-care measurements of salivary biomarkers of periodontitis. Ann. N. Y. Acad. Sci. 2007, 1098, 411-428.
132. Berek, J. S., Bast, R. C., Jr., Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 1995, 76, 2092-2096.
133. Terry, K. L., Sluss, P. M., Skates, S. J., Mok, S. C. et al., Blood and urine markers for ovarian cancer: A comprehensive review. Dis. Markers 2004, 20, 53-70.
134. Bast, R. C., Jr., Knauf, S., Epenetos, A., Dhokia, B. et al., Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer 1991, 68, 1758-1763.
135. Feng, H., Ghazizadeh, M., Konishi, H., Araki, T., Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn. J. Clin. Oncol. 2002, 32, 526-529.
136. Thorisson., G. A., Smith, A. V., Krishnan, L., Stein, L. D., The International HapMap Project Web site. Genome Res. 2005, 15, 1592-1593.
137. Nedelkov, D., Tubbs, K. A., Niederkofler, E. E., Kiernan, U. A., Nelson, R. W., High-throughput comprehensive analysis of human plasma proteins: A step toward population proteomics. Anal. Chem. 2004, 76, 1733-1737.
138. Mathew, J. P., Taylor, B. S., Bader, G. D., Pyarajan, S. et al., From bytes to bedside: Data integration and computational biology for translational cancer research. PLoS Comput. Biol. 2007, 3, e12.
139. Narayanan, R., Bioinformatics approaches to cancer gene discovery. Methods Mol. Biol. 2007, 360, 13-31.
140. Xie, Q., Ratnasinghe, L. D., Hong, H., Perkins, R. et al., Decision forest analysis of 61 single nucleotide polymorphisms in a case-control study of esophageal cancer; a novel method. BMC Bioinformatics 2005, 6, S4.
141. Wilson, R. D., Genomics: New technology for obstetrics. Genetics Committee of the SOGC. J. Obstet. Gynaecol. Can. 2005, 27, 63-75.
142. Verma, M., Wright, G. L., Jr., Hanash, S. M., Gopal-Srivastava, R. et al. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann. N. Y. Acad. Sci. 2001, 946, 103-115.
143. Anderson, N. L., Anderson, N. G., The human plasma proteome: History, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
144. Muthusamy, B., Hanumanthu, G., Suresh, S., Rekha, B. et al., Plasma Proteome Database as a resource for proteomics research. Proteomics 2005, 5, 3531-3536.
145. Hu, S., Loo, J. A., Wong, D. T. Human body fluid proteome analysis. Proteomics 2006, 6, 6326-6353.
146. Liang, S. L., Chan, D. W., Enzymes and related proteins as cancer biomarkers: A proteomic approach. Clin. Chim. Acta 2007, 381, 93-97.
147. Daly, B., Ozols, R. F., The search for predictive patterns in ovarian cancer: Proteomics meets bioinformatics. Cancer Cell. 2002, 1, 111-112.
148. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J. et al., Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 369, 572-677.
149. Zhan, M., Sorace, J. M., A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 2003, 4, 24.
150. Alexe, G., Alexe, S., Liotta, L. A., Petricoin, E. et al., Ovarian cancer detection by logical analysis of proteomic data. Proteomics 2004, 4, 766-783.
151. Mead, J. A., Shadforth, I. P., Bessant, C., Public proteomic MS repositories and pipelines: Available tools and biological applications. Proteomics 2007, 7, 2769-2786.
152. Becker, K. G., Hosack, D. A., Dennis, G., Jr., Lempicki, R. A. et al., PubMatrix: A tool for multiplex literature mining. BMC Bioinformatics 2003, 4, 61.
153. Pospisil, P., Iyer, L. K., Adelstein, S. J., Kassis, A. I., A combined approach to data mining of textual and structured data to identify cancer-related targets. BMC Bioinformatics 2006, 7, 354.
154. Rai, A. J., Zhang, Z., Rosenzweig, J., Shih, I. M. et al., Proteomic approaches to tumor marker discovery. Arch. Pathol. Lab. Med. 2002, 126, 1518-1526.
155. Ye, B., Cramer, D. W., Skates, S. J., Gygi, S. P. et al., Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 2003, 9, 2904-2911.
156. Kozak, K. R., Amneus, M. W., Pusey, S. M., Su, F. et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis. Proc. Natl. Acad. Sci. USA 2003, 100, 12343-12348.
157. Vlahou, A., Schorge, J. O., Gregory, B. W., Coleman, R. L., Diagnosis of ovarian cancer using decision tree classification of mass spectral data. J. Biomed. Biotechnol. 2003, 2003, 308-314.
158. Burtis, C. A., Ashwood, E. R., Tietz Textbook of Clinical Chemistry, 2nd Edn., W. B. Saunders Co., Philadelphia 1994, p. 674.
159. Zhang, Z., Bast, R. C., Jr., Fung, E. T., Yu, Y. et al., A panel of three potential biomarkers discovered from serum proteomic profiling improves sensitivity of CA-125 in the detection of early stage ovarian cancer - A multi-institutional study. Proc. AACR 2003, Abstract 5739.
160. Cho, W. S. C., Yip, T. T. C., Yip, C., Yip, V. et al., Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin. Cancer Res. 2004, 10, 43-52.
161. Hlavaty, J. J., Partin, A. W., Shue, M. J., Mangold, L. A. et al., Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. Urology 2003, 61, 1261-1265.
162. Zhao, C., Annamalai, L., Guo, C., Kothandaraman, N. et al., Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia 2007, 9, 1-7.
163. Diamandis, E. P., Molecular and cellular mass spectrometry as a diagnostic and a cancer biomarker discovery tool opportunities and potential limitations. Mol. Cell. Proteomics 2004, 3, 367-378.
164. Ye, B., Gagnon, A., Mok, S. C., Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Rev. Proteomics 2007, 4, 121-131.
165. Scambia, G., Benedetti Panici, P., Baiocchi, G., Perrone, L. et al. CA15-3 as a tumour marker in gynecological malignancies. Gynecol. Oncol. 1988, 30, 265-273.
166. Skates, S., Iliopoulos, O. Molecular markers for early detection of renal carcinoma: Investigative approach. Clin. Cancer Res. 2004, 10, 6296S-6301S.
167. McIntosh, M. W., Drescher, C., Karlan, B., Scholler, N. et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol. Oncol. 2004, 95, 9-15.
168. Moore, L. E., Fung, E. T, McGuire, M., Rabkin, C. C. et al., Evaluation of apolipoprotein A1 and post translationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev. 2006, 15, 1641-1646.
169. Rifai, N., Gillette, M. A., Carr, S. A., Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
170. Hellstrom, I., Raycraft, J., Hayden-Ledbetter, M., Ledbetter, J. A. et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003, 63, 3695-3700.
171. Diamandis, E. P., Scorilas, A., Fracchioli, S., Van Gramberen, M. et al., Human kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J. Clin. Oncol. 2003, 21, 1035-1043.
172. Kim, J. H., Herlyn. D., Wong, K. K., Park, D. C., Schorge, J. O., Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin. Cancer Res. 2003, 9, 4782-4791.
173. Luo, L. Y., Katsaros, D., Scorilas, A., Fracchioli, S. et al., The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res. 2003, 63, 807-811.
174. Kim, J. H., Skates, S. J., Uede, T., Wong, K. K., Schorge, J. O., Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002, 287, 1671-1679.